Generic Semaglutide in 2026: Where Is It Actually Approved?

Generic semaglutide, meaning a version of Novo Nordisk's molecule approved by a national regulator by comparison with Ozempic or Wegovy, is approved in 2026 in Canada, India and Brazil. India's brands launched on 21 March 2026; in Canada, Apotex launched Apo-Semaglutide Injection on 14 May 2026 and Dr. Reddy's launched its Semaglutide Injection on 16 May 2026, both referencing Ozempic (Apotex news release, 14 May 2026; Pearce IP, 14 May 2026); in Brazil, EMS began distributing Ozivy to pharmacies in June 2026 (Exame, 16 June 2026). It is not approved in the United States, the European Union or China, and the reasons differ in each case: unexpired patents in the US, supplementary protection certificates in the EU, and regulatory data protection in China.

The dividing line is the compound patent. Novo Nordisk's core semaglutide patent family expired in China, India and Brazil in March 2026 (Pearce IP, 21 March 2026; NeoFeed, 20 April 2026; Bloomberg via Swissinfo, 6 May 2026), and in Canada the company let its patent lapse years earlier. In the US and Japan, extensions run to 2032 and 2031 respectively (Fortune, 17 June 2025); in Europe, supplementary protection certificates run to 2031 (Reddie & Grose, patent attorneys, 9 February 2026). So the same molecule is a generic in Toronto and Mumbai and a protected brand in Boston and Berlin.

This page walks through each country with the regulator, the company and the date for every approval we could verify against a primary or named source as of 14 September 2026. It deliberately does not quote prices, because the only prices that mean anything are the ones a regulator or manufacturer publishes for your market on a given day, and it does not tell you what to take. Whether a generic is appropriate for you, whether it can replace what you are on, and how the pen you are handed differs from the one you know are questions for the prescriber who wrote the prescription and the pharmacist who fills it.

One caveat that matters for every section below: approval and availability are two different events. A regulator's registration is dated and public; a pharmacy shelf is neither. In Brazil, for example, EMS's Ozivy was registered in May 2026, had its price ceiling fixed by CMED, the pricing chamber, at the end of May (Conselho Federal de Farmacia, 1 June 2026), and began reaching the main pharmacy chains in state capitals in the week of 15 June 2026 (Exame, 16 June 2026); the five products approved on 29 July 2026 still needed a CMED maximum price before they could be sold (Exame, 29 July 2026).

A generic medicine contains the same active ingredient as an approved reference product, in the same strength and route, and is authorised by a regulator after the applicant demonstrates it performs the same way. For a synthetic peptide like semaglutide, regulators such as Health Canada and Anvisa have handled these applications under their generic or comparative pathways, which is why the Canadian releases say 'generic version of Ozempic' and the Brazilian approvals were registered 'by comparison with Ozempic' (Health Canada, 28 April 2026; Exame, 29 July 2026). The word 'generic' therefore carries a promise: a named manufacturer, an inspected factory, a regulator's file, a label, and a pharmacy that is accountable for what it dispensed.

Compounded semaglutide is something else. A compounding pharmacy prepares a medicine for an individual prescription rather than manufacturing an approved product, and the US Food and Drug Administration states that compounded drugs are not approved by FDA and do not go through its review for safety, effectiveness and quality (FDA, page updated 1 April 2026). Compounding of semaglutide expanded during the US shortage, which the FDA declared resolved on 21 February 2025, with enforcement discretion for compounders ending on 22 April 2025 for pharmacies and 22 May 2025 for outsourcing facilities. Compounded is not generic, and searching for one will not find the other. The full picture is on the compounded semaglutide page.

Counterfeit product is not a category of medicine at all. It is a crime that imitates a brand's packaging. On 14 April 2025 the FDA warned consumers about counterfeit Ozempic in the US supply chain: several hundred units seized on 9 April 2025, labeled with lot number PAR0362 and serial numbers beginning 51746517, with identity, quality and safety unknown at the time of the alert. On 5 December 2025 the FDA issued a further alert on counterfeit Ozempic labeled with lot number PAR1229, which the agency notes is also an authentic lot number. The World Health Organization issued a global alert on falsified Ozempic in June 2024. The practical rule follows from the definitions: a genuine generic reaches you through a licensed pharmacy with a regulator's registration behind it, and anything sold as 'generic Ozempic' outside that chain, particularly in a country where no generic is approved, is either compounded or counterfeit.

If you want to compare the reference products these generics copy, the Ozempic label reference and the Wegovy label reference summarise the FDA prescribing information for each.

Canada is the clearest case, and the story starts with paperwork. Novo Nordisk paid the maintenance fee on Canadian patent 2,601,784 through 2018 and did not pay it in 2019; under Canadian rules a lapsed patent cannot be revived, as a Canadian Intellectual Property Office notice quoted by Fortune warned. Novo Nordisk told Fortune that intellectual-property decisions are 'carefully considered at a global level' (Fortune, 17 June 2025). With the patent gone and regulatory data protection running out in early 2026, generic applications could proceed.

On 28 April 2026, Health Canada announced it had approved a generic semaglutide injection from Dr. Reddy's Laboratories, referencing Ozempic, for the once-weekly treatment of adults with type 2 diabetes, and said it was the first G7 country to authorise a generic version of semaglutide, with eight further submissions under review. On 1 May 2026 it approved a second, from Apotex, also referencing Ozempic, with seven submissions still in the queue. On 29 June 2026 it approved Apotex's Sevmia, the first generic referencing Wegovy, for chronic weight management in patients 12 years and older, and noted six more submissions under review. Each of those figures comes from the corresponding Health Canada news release.

Health Canada did not publish launch dates or prices, beyond its general observation that generics in Canada are typically 45 to 90 percent cheaper than brands; the manufacturers did. Apotex announced the commercial launch of Apo-Semaglutide Injection on 14 May 2026, stating that initial inventory was shipping to wholesalers and would be on pharmacy shelves across Canada within the coming weeks (Apotex news release, 14 May 2026). Dr. Reddy's announced the Canadian launch of its Semaglutide Injection on 16 May 2026 (Pearce IP, 14 May 2026, updated with the Dr. Reddy's announcement). Global News reported on 20 May 2026 that Shoppers Drug Mart and Rexall were receiving their first inventory that week. Both launched products reference Ozempic; we did not find a published launch date for Sevmia, the Wegovy-referencing generic approved on 29 June 2026. Sandoz's chief executive told Fortune in June 2025 that the company had filed in Canada and expected approval in the first quarter of 2026; as of 14 September 2026 the three Health Canada approvals we could verify are the two from Apotex and one from Dr. Reddy's.

For a Canadian reader, the questions belong to the pharmacy counter: whether a given generic is stocked, whether a provincial or private plan lists it, and whether the pen and needle differ from the brand you were trained on. If a plan has said no to the brand, the insurance denial scenario covers what to ask and what to keep on file.

India moved fastest and widest. Novo Nordisk's core Indian semaglutide patent expired in March 2026, and on 21 March 2026 several manufacturers launched on what the patent-law firm Pearce IP called a 'Day 1 entry', each with approval from the Drugs Controller General of India (Pearce IP, 21 March 2026). Dr. Reddy's launched Obeda in a pre-filled pen for type 2 diabetes and was reported as the first Indian company to receive DCGI approval. Zydus Lifesciences launched Semaglyn, Mashema and Alterme for type 2 diabetes and obesity, and signed a co-marketing agreement with Lupin on 17 March 2026. Alkem Laboratories launched Semasize, Obesema and Hepaglide; Sun Pharma launched Noveltreat and Sematrinity for chronic weight management and type 2 diabetes; Glenmark launched GLIPIQ for type 2 diabetes. Business Today reported Mankind among the first movers as well (19 March 2026).

Two things stand out. First, several Indian approvals cover both the diabetes and the weight-management indication from launch, which is not the pattern in Canada or Brazil, where the first approvals referenced Ozempic and diabetes only. Second, the sheer number of brands means an Indian pharmacy may offer the same molecule under many names, in pre-filled pens, reusable multi-dose pens and, in Glenmark's case, vials. A different device is a different set of handling instructions, and that is the pharmacist's conversation, not a tracker's.

Indian manufacturers publish their own prices and Indian business press quotes them; we do not repeat figures here because they change and because a list price in one city is not a price in another. If the cost of a GLP-1 is the question, the cost and savings guide explains the factors without pretending to know your number.

Brazil is the most interesting regulatory story of 2026 because of a technicality. Novo Nordisk's semaglutide patent expired in Brazil on 20 March 2026 (NeoFeed, 20 April 2026). But Anvisa could not simply register a 'generic' of Ozempic, because Brazilian generics are registered against a reference medicine and the domestic manufacturers were making semaglutide synthetically rather than by Novo Nordisk's process. So the first wave was registered as new synthetic products rather than as genericos.

The sequence, from Anvisa's own publications and the Conselho Federal de Farmacia's reporting: in May 2026 Anvisa registered Ozivy, EMS's synthetic semaglutide pen, the first domestically made semaglutide approved after the patent expired, for adults with type 2 diabetes. CMED fixed Ozivy's maximum price at the end of May 2026 (CFF, 1 June 2026), and EMS began distributing it to the main pharmacy chains in state capitals in the week of 15 June 2026, with national coverage expected by July (Exame, 16 June 2026). On 10 July 2026 Anvisa published Ozivy's inclusion in the Lista de Medicamentos de Referencia in the Diario Oficial da Uniao, making it the quality, safety and efficacy benchmark for future synthetic semaglutide generics and similars (CFF, 15 July 2026). On 29 July 2026 Anvisa approved five more synthetic semaglutides for type 2 diabetes in a single decision: Owozy (Avita Care), Seemasun (Sun Farmaceutica do Brasil), Zempneo (Brainfarma), Semavy (Cosmed, part of Hypera) and Orsema (Ranbaxy Farmaceutica), all registered by comparison with Ozempic and all still awaiting a CMED price before sale (Exame, 29 July 2026). In August 2026 the CFF reported Anvisa's approval of the first product formally classed as a generico, from EMS, alongside a 'similar' from Germed (CFF, 17 August 2026). Brazilian trade press has since listed further EMS and Germed similars registered at the end of August 2026 (NC News, 4 September 2026).

What about Eurofarma's Poviztra and Extensior? They are frequently described online as Brazilian generics, and they are not. Both contain Novo Nordisk's own semaglutide, manufactured by Novo Nordisk and marketed in Brazil by Eurofarma under a partnership, with Extensior positioned for type 2 diabetes and Poviztra for obesity and overweight with comorbidities (NeoFeed, 20 April 2026; ISTOE Dinheiro, 16 April 2026). Eurofarma's executives call them the original biological molecule under a second brand. They matter to this page because the indications of the domestic products are not settled in the sources: the CFF's August note described the EMS generic as indicated for type 2 diabetes and, at specific doses, for obesity and overweight (CFF, 17 August 2026), while NC News lists every 2026 synthetic as a type 2 diabetes registration (NC News, 4 September 2026), and Poviztra, which is a Novo Nordisk-made product under a Eurofarma brand, is the only obesity-indicated Brazilian-branded semaglutide our sources name; Wegovy itself remains on the Brazilian market. Whether a specific synthetic brand carries a weight-management indication is a question for its Anvisa bula and your prescriber, not for a summary page.

China has the patent expiry without the approvals. The core Chinese patent expired in March 2026. Hangzhou Jiuyuan Genetic Biopharmaceutical's application for Jikeqin, referencing Wegovy, was accepted by the National Medical Products Administration on 25 February 2026 (Pearce IP, 25 February 2026). Yet Novo Nordisk said in May 2026 that it expected no generic in China until 2027, because Ozempic holds regulatory data protection under the China-Switzerland Free Trade Agreement until April 2027, and Jiuyuan disclosed that its review was suspended on data-protection grounds (Bloomberg via Swissinfo, 6 May 2026). As of the latest statements we could verify, no NMPA approval of a follow-on semaglutide had been announced.

The United States has neither. There is no FDA-approved generic semaglutide on sale. What exists is a tentative approval: on 10 April 2026 the FDA tentatively approved Apotex's abbreviated new drug application for a generic version of Ozempic, developed with Orbicular. A tentative approval means the product meets the FDA's standards but cannot be marketed while the reference product's patents and exclusivities stand (Apotex, 10 April 2026). Fortune reported in June 2025 that US protection on Ozempic runs to 2032. In the meantime, anything sold in the US as generic semaglutide is either a compounded preparation, which the FDA does not approve, or a counterfeit, which the FDA seizes. The compounded semaglutide page covers the first case; the FDA's April 2025 counterfeit alert covers the second.

The European Union sits between. The underlying compound patent's term is running out, but supplementary protection certificates, which extend protection to compensate for the time spent in regulatory review, keep Novo Nordisk's exclusivity in place; Reddie & Grose expects loss of exclusivity in Europe in 2031. We found no EMA-authorised generic semaglutide as of September 2026, and no MHRA-authorised one in the UK. European readers searching for a generic will find brand product, cross-border offers of uncertain origin, and, in some countries, compounding under national pharmacy rules.

If you move between a brand and a generic under a prescriber's direction, the useful record is small: product name, manufacturer, lot number, the date the switch happened, and how the following weeks felt. GLP-1 Tracker, a free iPhone app, logs each dose with a note field for exactly that, alongside injection sites, weight and side effects, so the change is visible in your history rather than reconstructed from memory. Which product you take is never the app's call. The switching medications how-to shows how to keep the timeline clean.